Caris Life Sciences

A precise analysis of DNA, RNA, and protein biomarkers for evidence-based selection of appropriate cancer therapies.

Single assay that analyzes total nucleic acids for both DNA and RNA, providing a comprehensive molecular blueprint that saves tissue without compromis...

A comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions.

Utilizes advanced technologies for biomarker identification to assist oncologists in planning treatment strategies.

HRD is an important biomarker for advanced ovarian cancer and PARP inhibitor therapy. It identifies tumors that exhibit HRD, which can help inform tre...

Caris molecular profiling includes microsatellite instability (MSI) testing via next-generation sequencing (NGS). MSI is caused by failure of the DNA ...

Comprehensive molecular profiling includes next-generation sequencing of all 23,000 genes to provide clinically actionable information.

Testing for PD-L1 expression in tumors to guide immunotherapy decisions.

Utilizes advanced technologies and comprehensive approach to analyze DNA, RNA, and proteins to reveal a molecular blueprint that guides more precise a...

Analyzing the molecular composition of tumors to inform treatment options.

A measure of the number of mutations within the tumor's genes.

A pan-tumor biomarker that indicates a cancer may respond more effectively to immunotherapies, measuring the total number of mutations that result in ...

offers unparalleled precision medicine services that are designed to maximize the chances of success for clinical trials and address many patient accr...

provides information and data by using the power of DEAN artificial intelligence and machine learning technology to provide oncologists with the most ...

MI Cancer Seek™ is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved...

On-demand platform for clinicians, pathologists, and scientists to interact with leading cancer experts to decipher complex data and provide therapeut...

Considered for first-line metastatic colorectal cancer treatment.

Tailoring cancer treatment to the specific biomarkers found in the patient's cancer.

Increases access to clinical trials through this platform.

Connects physicians and patients with available clinical trials.

Helps to direct patients to clinical trials recruiting for specific genotypes.

Assists in identifying clinical trials that match a patient’s cancer profile.

Includes Caris GPSai™, Caris FOLFIRSTai™ for enhanced molecular insights.

Supports marginalized women and children through training in health and nutrition, offering counseling and mentoring in physical, emotional and spirit...

A measure of the instability of certain regions of the genome, which can inform treatment options.

is an AI that uses genomic and transcriptomic data to elucidate tumor origin.

Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) for every patient. Includes next-generation sequencing of all 23,000 genes.

Genotyping is included with all Caris orders and helps in understanding patient immune response.

Identifies key molecular features of cancer and provides clinical insights to aid oncologists in personalizing cancer therapies.

Caris defines Comprehensive Genomic Profiling with 23,000 DNA Genes, 60,000 RNA Transcripts, and Protein Analysis. This molecular profiling approach a...

Whole Exome Sequencing (WES), which alongside Whole Transcriptome Sequencing (WTS), provides extensive proteomic testing services and advanced machine...

A high-throughput, next generation sequencing-based assay analyzing the whole human exome of approximately 23,000 DNA genes.

A comprehensive program for orphans and vulnerable children, focusing on adolescent girls and young women, providing support for HIV-infected individu...

The first commercially available AI signature for the prediction of benefit from standard chemotherapy, validated in independent datasets.

Evaluates protein biomarkers through an extensive immunohistochemical panel.

Coordinates and funds surgeries for those who cannot access or afford medical care, and provides assistance during disasters.

Offers ISH for select genes to provide higher resolution to IHC results.

RNA-based analysis, via Whole Transcriptome Sequencing, is the best method to detect clinically relevant aberrations, because the presence of RNA tran...

Enriches samples for DNA and RNA derived from tumors, achieving over 95% detection rates.

Fighting cancer by knowing what it looks like at the molecular level can lead to better treatment options.

which is powered by DEAN, identifies unique molecular signatures by cancer subtype to help predict which patients may respond to specific treatments, ...

Providing detailed genetic information for treatment.

Additional sequencing-based features are reported including gLOH, HRD, HLA Genotype, Chromosomal Alterations, Viruses (HPV 16 & 18, EBV, MCPyV).

Advanced genomic analysis for all tumor types.

Enables Whole Exome (DNA) and Whole Transcriptome (RNA) sequencing on every patient.

Caris’ Whole Transcriptome Sequencing (WTS) uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patient tumor...

RNA sequencing for 23,000+ genes including gene fusions, variant transcripts & gene expressions.

Determines drugs with potential lack of benefit, avoiding unnecessary toxicities and costs.

Supported by the Catholic Medical Mission Board, focuses on maternal-child health, nutrition, vaccination, family planning, HIV/tuberculosis and infec...

Caris GPSai™, a Genomic Probability Score, uses whole exome (DNA) and whole transcriptome (RNA) sequencing coupled with trained and validated neural n...

has been demonstrated to accurately identify tumor origin using molecular information.